Trial
NCT06341712
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Ipsen
Collaborators
—
Condition
Osteosarcoma
Intervention
Cabozantinib
Why stopped
The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-31